Withaferin A was found to be dual activator of LXR and FXR, and Withaferin A exerted anti-tumor effects without inducing hepatic lipid accumulation, suggesting the important role of LXR agonists in anti-tumor (Shiragannavar et al. 2020, 2023). The gene discussed is NR1H4; the disease is neoplasm.